Having trouble accessing articles? Reset your cache.

Briakinumab: Phase III data

The double-blind Phase III M10-255 trial in 317 patients showed that briakinumab met the co-primary endpoints of a significantly greater proportion of patients achieving a PASI 75 response

Read the full 280 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE